CVS Health (NYSE: CVS) has recently announced the appointment of four new members to its board of directors, following productive discussions with Glenview Capital Management. The new board members include Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman.
Leslie Norwalk, who serves as strategic counsel to healthcare companies, will join the health services committee. Larry Robbins, the CEO of Glenview Capital Management, brings 30 years of experience as an institutional investor with a significant healthcare focus. Guy Sansone, currently the chairman and CEO of H2 Health, a leading regional provider of physical rehabilitation services, will join the audit committee. Doug Shulman, the chairman of OneMain Holdings, Inc., and former IRS Commissioner, will join the management planning and development committee.
With these appointments, the CVS Health board now comprises 16 members.
CVS Health and Glenview Capital Management have also entered into a confidentiality agreement under which Glenview has agreed to customary confidentiality, standstill, and other provisions. This agreement will be filed on a form 8-K with the U.S. Securities and Exchange Commission.
The appointments come as CVS Health continues to focus on driving greater financial and operational performance. The company aims to build momentum across its integrated model and take actions that are positive for its long-term success, while driving innovation and performance in its individual businesses and overall operations.
The addition of these four experienced thought leaders to the board further sharpens the company's focus on executing its strategy to build a world of health around every consumer, as it seeks to improve total cost of care and customer experience in healthcare.
CVS Health is the leading health solutions company, delivering care through its local presence, digital channels, and over 300,000 dedicated colleagues. The company aims to reach more people and improve the health of communities across America by helping individuals manage chronic diseases, stay compliant with medications, and access affordable health and wellness services in convenient ways.
As CVS Health continues to evolve and expand its board, the company is positioning itself to navigate the ever-changing healthcare landscape and drive sustainable value for its stakeholders. As a result of these announcements, the company's shares have moved 4.0% on the market, and are now trading at a price of $55.34. If you want to know more, read the company's complete 8-K report here.
